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Antimicrobial peptides/proteins are ancient and naturally- 
occurring antibiotics in innate immune responses in a variety 
of organisms. Additionally, these peptides have been recog-
nized as important signaling molecules in regulation of both 
innate and adaptive immunity. During mycobacterial infec-
tion, antimicrobial peptides including cathelicidin, defensin, 
and hepcidin have antimicrobial activities against mycobac-
teria, making them promising candidates for future drug 
development. Additionally, antimicrobial peptides act as im-
munomodulators in infectious and inflammatory conditions. 
Multiple crucial functions of cathelicidins in antimycobac-
terial immune defense have been characterized not only in 
terms of direct killing of mycobacteria but also as innate im-
mune regulators, i.e., in secretion of cytokines and chemo-
kines, and mediating autophagy activation. Defensin families 
are also important during mycobacterial infection and con-
tribute to antimycobacterial defense and inhibition of myco-
bacterial growth both in vitro and in vivo. Hepcidin, although 
its role in mycobacterial infection has not yet been charac-
terized, exerts antimycobacterial effects in activated macro-
phages. The present review focuses on recent efforts to elu-




Tuberculosis remains one of the most serious infectious dis-
eases globally. In 2009, it had an estimated incidence of 9.4 
million  cases  and  1.7  million  people  died  of  tuberculosis 
globally.  Generally,  one  third  of  the  world’s  population  is 
thought to be latently infected (1). Upon infection, Mycobac-
terium tuberculosis invades and successfully replicate inside 
host  macrophages.  Although  infected  host  cells  can  harbor 
viable mycobacteria, only ~10% of infected people develop 
tuberculosis (2). Therefore, the interaction between bacterial 
pathogenesis  and  the  magnitude  of  the  host  immune  re-
sponse  determines  the  outcome  of  the  disease  (3). 
　Earlier studies demonstrated the potential therapeutic roles 
of antimicrobial peptides in a variety of human diseases, in-
cluding atopic dermatitis, cystic fibrosis and Crohn's disease 
(4). Recent studies have emphasized the roles of cathelicidin 
LL-37 in antimycobacterial immune defense, especially in hu-
man monocytes/macrophages (5,6). Vitamin D was found to 
be important in the regulation of LL-37 expression in mono-
cytes,  macrophages,  and  respiratory  epithelial  cells  (6,7). 
Defensins have been widely studied as an antimicrobial pep-
tide  family  present  in  airway  fluid  and  reported  to  possess 
antimicrobial activities, including those against mycobacterial 
infection (8,9). Additionally, hepcidin, an antimicrobial pep-
tide that regulates iron homeostasis, inhibits M. tuberculosis 
growth in vitro  and  inflicts  structural  damage  on  this  noto-
rious  pathogen  (10).  Moreover,  these  antimicrobial  peptide 
molecules influence a variety of physiological processes and 
also  function  as  crucial  signaling  mediators  in  host  defense 
and  inflammation  (11). 
　Despite  these  advances  in  research  of  the  role  of  anti-
microbial peptides in mycobacterial infection, the regulatory 
mechanisms of these antimicrobial peptides and their exact 
roles in inflammation during mycobacterial infection remain Antimicrobial Peptides in Mycobacterial Infection
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Figure 1. A schematic diagram for the role of antimicrobial peptides such as cathelicidins and defensins in host immune system. Left diagram
shows biological effects of cathelicidin (hCAP-18/LL-37) in immunity. hCAP-18/LL-37 is synthesized and released from epithelial cells in response
to microbial infection or physical injury. hCAP-18/LL-37 participates in the recruitment of neutrophils and other circulating cells including 
monocytes/macrophages at sites of infection by chemotaxis through secretion of several cytokines/chemokines. Release of hCAP-18/LL-37 from
keratinocytes results in induced wound healing. Also, they contribute to direct killing activity against invading pathogens and to indirect 
antimicrobial activity by promoting autophagy activation/maturation in monocytes/macrophages. Right diagram shows immunological functions 
of defensins in various immune cells. Defensins induced by various physiological sitimuli including TLRs or infection. α-defensins are synthesized
and released from monocytes/macrophages or neutrophils/eosinophils, whereas β-defensins are synthesized and released from not only their
cells but also DCs, airway epitheliums or skin. Released peptides have direct antimicrobial killing effects and they also have indirect killing
effects by interacting with various target cells and tissues to promote secondary responses that may be crucial for modulating inflammation,
the recruitment of immune cells, and activation/maturation of several type of immune cell.
t o  b e  c l a r i f i e d .  T h u s ,  u n d e r s tanding  the  molecular  mecha-
nisms of expression of antimicrobial peptides and their role 
as  immune  modulators  during  the  host  innate  response  to 
mycobacteria will help in the design of new therapies against 
tuberculosis. Due to the increasing global incidence of multi-
drug-resistant tuberculosis, peptide-derived microbicides rep-
resent promising candidate therapeutics in the struggle against 
resistant  mycobacteria.
GENERAL OVERVIEW OF ANTIMICROBIAL 
PEPTIDES/PROTEINS
Antimicrobial defense peptides/proteins can be produced by 
activated  macrophages and  assist  in  elimination  of  ingested 
bacteria  (4,5).  Antimicrobial  peptides  such  as  cathelicidins 
and defensins play a crucial role in biological processes, in-
cluding antimicrobial activities and immunomodulatory func-
tions (summarized in Fig. 1). Cathelicidins are bipartite mole-
cules consisting of an N-terminal cathelin domain and a C-ter-
minal domain, which has antimicrobial activity (12,13).  The 
N-terminal cathelin domain is known as a hallmark of the in-
tracellular storage part of cathelicidins (12,13). Cathelicidins 
show constitutive and/or inducible expression in various cells 
and  tissues  (12,13).  Their  tissue/cell-specific  expression  is 
regulated by several stimuli including infection of microbes, 
inflammatory  cytokines  (13-15).  Many  studies  reported  that Antimicrobial Peptides in Mycobacterial Infection
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hCAP-18/LL-37 contributes to elimination of bacteria (14), sys-
temic  protection  against  microbial  invasion  (13),  chemo-
taxis-attraction through secretion of several cytokines/chemo-
kines (16), wound healing (16) and autophagy activation/ma-
turation  (17). 
　Defensins are antimicrobial/cytotoxic peptides which con-
tain  29∼35  amino  acid  residues,  including  6  invariant  cys-
teine residues (18). Defensins are expressed by various phys-
iological/biological  stimuli  including  TLRs  or  infection  (18). 
The  antimicrobial  spectrum  of  defensins  include  not  only 
gram positive microbes but also gram negative bacteria, in-
cluding mycobacteria, Treponema pallidum, fungi, and some 
viruses (18-20). Defensins exert nonspecific antimicrobial/cy-
totoxic  activity  against  mammalian  target  cells  and  micro-
organisms  (18).  In  addition  to  their  antimicrobial/cytotoxic 
properties,  some  defensins  act  as  opsonins  (18),  contribute 
to  selective  chemo-attractants  for  monocytes  (18),  DCs  and 
T  cells  (21),  and  promote  to  wound  healing  (8,22,23)  and 
regulation  of  inflammation  (24,25).
CATHELICIDIN hCAP-18/LL-37
The cathelicidin family, a key member of host defense pep-
tide families, is derived from leukocytes and epithelial cells 
and has an important role in elimination of pathogenic mi-
crobes (13-15,26). Various inflammatory or infectious stimuli 
can  induce  cathelicidin  LL-37,  which  then  exhibits  anti-
microbial activity against a number of bacteria and fungi (12, 
14,22). hCAP-18/LL-37 is currently the only identified human 
cathelicidin,  and  profoundly  affects  multiple  biological  and 
pathological conditions (14, 26). Cathelicidins contain a con-
served N-terminal cathelin domain and a variable C-terminal 
cationic antimicrobial domain that becomes active and has an-
timicrobial activity. The mature peptide LL-37 comprises the 
C-terminal portion and is expressed in various cell and tissue 
types, including neutrophils, monocytes, keratinocytes, lym-
phocytes, and epithelial cells of the skin, testis, and the gas-
trointestinal  and  respiratory  tracts  (12,15). 
    Accumulating evidence supports an early defensive role for 
LL-37  at  various  sites.  During  mycobacterial  infection,  the 
highest expression of LL-37 was observed in alveolar macro-
phages  (27).  Other  studies  showed  the  importance  of  neu-
trophils in host defense against mycobacteria. When the over-
all  immunity  of  blood  cells  to  mycobacterial  infection  was 
evaluated in tuberculosis contactors, neutrophil counts were 
associated with a high risk of tuberculosis infection and re-
striction of mycobacterial growth (28). Additionally, the neu-
trophil peptides, cathelicidin LL-37 and lipocalin2 (Lcn2, also 
known  as  neutrophil  gelatinase-associated  lipocalin  [NGAL]) 
contributed  to  inhibition  of  mycobacterial  growth  and  im-
mune defense against tuberculosis (28). Earlier studies show-
ed that the synthetic peptide  LL-37 had broad antimicrobial 
activity in airway epithelial cells of the lung (29) and in bron-
choalveolar lavage fluids (30). Recently, we reported that M. 
ulcerans infection significantly induces antimicrobial peptide 
LL-37  in  human  primary  keratinocytes  via  TLR2-  and 
Dectin-1-dependent pathways (31). These reports emphasize 
a role for LL-37 in the early innate response to mycobacteria.
    In  mycobacterial  infection  of  human  mononuclear  cells, 
LL-37 is induced in a vitamin D-dependent manner, and plays 
an important role  in  inhibition  of  intracellular mycobacteria 
through  NADPH  oxidase  2-dependent  mechanisms  (6,32). 
Similarly,  M.  bovis  bacillus  Calmette-Guérin  (BCG)-induced 
up-regulation of the antimicrobial peptide cathelicidin LL-37 
in human epithelial cells was dependent on NADPH/ROS sig-
naling  pathways (33).  Of note, vitamin D is crucial  for the 
regulation of LL-37 induction, which can be expressed in hu-
man monocytes and respiratory epithelial cells through con-
version  of  vitamin  D  into  its a c t i v e  m e t a b o l i t e s  ( 6 , 7 ) .  
    Recently, emerging roles of autophagy in the regulation of 
innate  immune  functions  have  been  reported  (34).  Impor-
tantly, the autophagy pathway has been known to be a key 
defensive  mechanism  to  eliminate  M.  tuberculosis  through 
phagosomal  maturation  (35).  Our  recent  data  have  shown 
that vitamin D3 actively induces autophagy in human mono-
cytes and inhibits intracellular mycobacterial growth through 
increased autophagosomal maturation (17). In this study, we 
found that LL-37 plays an important role in the induction and 
maturation  of  autophagy  pathways  activated  by  vitamin  D3 
in human monocytes (17). LL-37 regulated the transcriptional 
expression of the autophagy-related genes beclin-1 and atg-5 
via C/EBP-β and MAPK activation (17). In addition, both de-
fensin-β4 and cathelicidin are induced by distinct pathways 
in human monocytes, but cooperate to activate the TLR2/1- 
mediated  antimycobacterial activity  (9).  Furthermore,  recent 
studies have shown that the mycobacterial lipoprotein LpqH 
actively induces autophagy through functional vitamin D re-
ceptor signaling and following induction of LL-37-dependent 
pathways  (36). 
    Besides autophagy regulation, additional novel functions of 
LL-37 have been reported: regulation of chemoattraction, in-
hibition of apoptosis, wound healing, angiogenesis, and re-Antimicrobial Peptides in Mycobacterial Infection
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lease of cytokines/chemokines (15,16). LL-37 can also func-
tion  as  an  immune  regulator,  mediating  M.  tuberculosis-in-
duced ROS release and production of pro-inflammatory cyto-
kines  and  chemokines  (32).  In  mice,  the  only  cathelicidin 
CRAMP  was  reported  and  structurally  similar,  but  shorter, 
than  human  LL-37  (12).  Both  human  LL-37  and  murine 
CRAMP has a similar pattern  of tissue distribution and bio-
lo g ic al  f un c ti on  (1 5).  F or  e x am pl e,  b ot h  L L- 37  an d CR AM P 
have been shown to be chemotactic for various immune cells, 
including neutrophils, monocytes, macrophages, and T cells 
(37,38). Further, increasing evidence indicates that various cy-
tokines and signals affect induction of cathelicidin expression 
(16). The Th1 cytokine IFN-γ up-regulates, whereas the Th2 
cytokine  IL-4  down-regulates,  TLR2/1-mediated induction of 
cathelicidin  (39).  In  this  way,  cell-mediated  immune  re-
sponses can cross-talk with innate immune pathways via cath-
elicidin and other AMPs (39). Collectively, these data suggest 
that cathelicidin LL-37 exerts not only direct antimicrobial ac-
tivity but is also an important immune modulator of autoph-
agy  regulation  during  mycobacterial  infection. 
DEFENSINS
Human defensins constitute a large portion of the pulmonary 
innate host defense system. Earlier studies showed that de-
fensins are present in high concentrations on respiratory epi-
thelia and selectively target microbial structures (40). Additio-
nally, defensins function as signaling molecules, which link 
the adaptive immune system to invader microorganisms (40). 
Similar to cathelicidins, precursors of defensins that contain 
a characteristic β-sheet-rich fold and a framework of six di-
sulfide-linked cysteines, require proteolytic cleavage for anti-
microbial activity (41). The small (3∼5 kDa) human cationic 
defensins are a delineated family of effectors of host defense, 
inflammation, and cytotoxicity (18). Defensins are divided in-
to three subfamilies: α-, β-, and θ-defensins (25). Six α
-defensins, four human β-defensins (HBD1∼4) (reviewed in 
Ref. 25), and additional β-defensin gene clusters have been 
identified  by  computational  analysis  (42). 
    High-throughput studies using microarray analyses of gene 
expression profiles of PBMCs from patients with tuberculosis 
and M. tuberculosis-infected healthy donors found that the ef-
fector molecules α-defensin 1, 3, and 4 are upregulated in 
patients with tuberculosis (43). Human defensins show syn-
ergy  with  antituberculous  drugs,  thus  suggesting  that  they 
may be a promising adjunct to antituberculous chemotherapy 
(44). Moreover, a protective role for α-defensin against my-
cobacterial infection has been reported in human eosinophils 
(19). α-defensin is induced in eosinophils upon stimulation 
with M. bovis BCG and lipomannan and shows a synergistic 
effect  with  eosinophil  cationic  protein  on  mycobacterial 
growth  inhibition  (19). 
    The human β-defensins HBD-1 and HBD-2 are predom-
inately expressed at epithelial sites, and less well defined than 
α-defensin family (23,25). Both HBD-1 and HBD-2 has bac-
tericidal  activity  against  both  Gram-positive  and  Gram-neg-
ative acteria (23,25). At least six  HBD-1  isoforms (range in 
length  from  36  to  47  amino  acids)  have  been  identified  in 
u r i n e ,  w h e r e a s  a  s i n g l e  i s o f o r m  o f  H B D - 2  ( 4 1  a m i n o  a c i d s 
in length) has been isolated from respiratory epithelial secre-
tions  and  saliva  (23).  While  HBD-1  is  constitutively  ex-
pressed,  HBD-2  is  upregulated  during  bacterial  infection  or 
in  response  to  endogenous  inflammatory  cytokines  (23,45, 
46), suggesting a role for HBD-2 in regulation of antimicrobial 
and inflammatory responses. During mycobacterial infection, 
HBD-2 can be transported into mycobacteria-containing mac-
rophage  phagosomes  to  exert  mycobactericidal  and  myco-
bacteristatic  activity  (20).  In  airway  epithelial  cells,  HBD-2 
mRNA is induced by M. bovis BCG infection and is upregu-
lated by TNF-α produced by M. bovis BCG-infected cells (46). 
HBD-2  expression  is  also  triggered  by  bacterial  LPS/TLR4 
stimulation through a CD14-dependent mechanism and ulti-
mately  results  in  activation  of  NF-κ B  (24). 
    Recent studies have emphasized the role of HBD4 in the 
innate immune defense against mycobacteria (9,35). TLR2/1- 
mediated  IL-1β is  required  for  up-regulation  of  HBD4  ex-
pression, which has antimicrobial activity against intracellular 
mycobacterial  infection  (9).  Moreover,  intratracheal  admin-
istration of l-isoleucine into mice infected with the antibiotic- 
sensitive strain H37Rv and a multidrug-resistant clinical isolate 
significantly up-regulated β-defensins 3 and 4 and inhibited 
bacillary  loads  (47).  M.  bovis  BCG-mediated  expression  of 
H B D 2  w a s  f o u n d  t o  b e  r e g u l a t e d  b y  t h e  p r o t e i n  k i n a s e  C  
(PKC), JNK and PI3K/Akt pathways in airway epithelial cells 
(46). Of interest, more highly virulent M. bovis strains exhibit 
lower murine defensin-β4 expression, and vice versa, during 
early infection (48). In experimental tuberculosis, initial ex-
pression of murine defensin-β3 and defensin-β4 in airway 
epithelial cells was correlated with temporary control of my-
cobacterial  growth  (49).  Additionally,  high  and  stable  pro-
duction of mouse β-defensins, mBD3 and mBD4 during la-
tent infection is associated with long-term control of myco-Antimicrobial Peptides in Mycobacterial Infection
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Table I. The roles of AMPs in immune system
AMPs Expressed cells organs Functions References
hCAP-18/LL-37 Neutrophails, monocytes/macrophages, 
keratinov\cytes, lymphocytes, epithelial 
cells and bronchoalveolar lavage fluids 
Elimination of pathogenic microbes (e.g. Mycobacteria, fungi)





Up-regulation of Th1 cytokine (e.g. IFN-γ)/down-refulation of 








Defensin Eosinophils, PBMCs, DCs, T-cells, 
monocytes/macrophages, airway 
epithelial cells
  α-defensin Up-regulation in TB patients
Protective effects against mycobacteria in eosinophils
Ref. 41
Ref. 19
  β-defensin Mycobactericidal and Mycobacteristatic activity
Regulation of Inflammation (e.g. TNF-α)
Activation of NFĸB





  θ-defensin Still unknown yet
Hepcidin hepatocytes, macrophages Homeostatic regulation of iron absorption, iron recycling and 
iron mobilization 
Inhibition of invasion of microbes and tumor cells 




bacterial  proliferation  (49).
  Similar to hCAP-18/LL-37, HBD-2 plays roles other than di-
rect antimicrobial action. These include chemotactic roles for 
immature dendritic cells and memory T cells through a che-
mokine  receptor  CCR6-dependent  mechanism.  This  mecha-
nism promotes adaptive immune responses by recruiting im-
mune cells to sites of microbial invasion (21). Unlike α- and 
β-defensins, θ-defensins are found in some non-human pri-
mates, but not in humans, gorillas, bonobos, or chimpanzees 
(50).  Tang  et  al.  first  isolated  a  trisulfide-containing  anti-
microbial  peptide,  termed  rhesus  theta  defensin  1  (RTD-1), 
from  granules  of  neutrophils  and  monocytes  of  the  rhesus 
macaque (51). Although θ-defensins have antimicrobial ac-
tivity  against  diverse  pathogens  (51-53),  especially  viruses 
(54-56),  there  is,  as  yet,  no  evidence  that  θ-defensins  are 
involved in defense against mycobacterial infection. The roles 
of antimicrobial peptides in mycobacterial infection are sum-
marized  in  Table  I.  Future  studies  will  reveal  the  multiple 
roles of various human defensins in the regulation of immune 
responses and host defense against mycobacterial infection.
HEPCIDIN
Hepcidin  is  a  cationic  amphipathic  bactericidal  peptide  pri-
marily produced in the liver, and acts as a homeostatic regu-
lator  of iron  absorption, recycling, and mobilization.  Its ex-
pression  is  markedly  induced  during  infectious  and  in-
flammatory conditions (57,58). Hepcidin is synthesized by iron 
loading  and  cytokine  IL-6,  and  decreased  by  anemia  and 
hypoxia.  The  major  mechanism  of  hepcidin  function  is 
thought  to  be  related  to  regulation  of  transmembrane  iron 
transport through binding  with ferroportin, an iron exporter 
expressed in hepatocytes and macrophages (59,60). The re-
sulting decrease in extracellular iron concentrations probably 
makes less available for invading microorganisms and tumor 
cells,  thereby  contributing  to  host  defense  and  controlling 
chronic diseases (57,58,61). As a novel mediator of innate im-
munity, hepcidin and related therapeutics are promising candi-
dates for the treatment of various diseases, such as hemochro-
matosis  and  anemia  from  chronic  inflammation  (57,58,61). 
    Hepcidin is expressed in macrophages after infection with 
the  intracellular  pathogens  M.  avium a n d  M.  tuberculosis. Antimicrobial Peptides in Mycobacterial Infection
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Stimulation  of  macrophages  with  mycobacteria  and  IFN-γ 
synergistically induced hepcidin mRNA and protein, which lo-
calized  to  the  mycobacteria-containing  phagosomes  (10). 
Additionally,  hepcidin  possesses  direct  antimicrobial  activity 
and  causes  damage  to  M.  tuberculosis ( 1 0 ) .  F u r t h e r  i n v e s -
tigation of the signaling mechanisms responsible for hepcidin 
mRNA expression showed that STAT1 and NF-κ B activation 
and  induction  of C/EBPβ were  involved in  IFN-γ and M. 
tuberculosis-induced  hepcidin  expression  by  macrophages 
(62). These data strongly suggest that M. tuberculosis-induced 
hepcidin expression by activated effector cells may contribute 
to host defense against mycobacteria. However, future studies 
are needed to clarify the exact roles and mechanisms of hep-
cidin expression in innate immune cells during mycobacterial 
infection.
CONCLUDING REMARKS
The  antimicrobial  peptides  can  contribute  to  antimyco-
bacterial innate immunity through direct (killing) and indirect 
(immune  modulation)  activities.  During  mycobacterial  in-
fection, the cathelicidin, defensin, and hepcidin peptide fami-
lies have been reported to exhibit antimicrobial activities and 
immunomodulatory functions. These peptides are produced 
i n  d i f f e r e n t  t y p e s  o f  i n n a t e  i m m u n e  c e l l s ,  s u c h  a s  m a c r o -
phages, neutrophils,  keratinoyctes and  epithelial cells.  As a 
bridge between the innate and adaptive immune responses, 
cathelicidin may contribute to host antibacterial defenses and 
dampen  harmful  inflammation.  Furthermore,  antimycobac-
terial immune defense is linked to cathelicidin expression and 
its role in mediating autophagy. IL-1β, a crucial cytokine in 
antimycobacterial  defense,  is  required  for  defensin  expre-
ssion, which is critical for innate immunity to mycobacteria. 
The  accumulating  data  will  enable  development  of  ther-
apeutic options and innovative antibiotics derived from host 
antimicrobial  peptides. 
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